Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Advanced Solid Tumor × talazoparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 12 Triple Negative Breast Neoplasms 5 Advanced Solid Tumors 4 Prostatic Neoplasms 3 Ovarian Neoplasms 3 Pancreatic Neoplasms 2 Neoplasms 2 Fallopian Tube Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Ovarian Epithelial 2 mCRPC 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 Sarcoma, Ewing 1 Recurrent Squamous Cell Lung Carcinoma 1 Recurrence 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neoplasm Metastasis 1 Leukemia, Myeloid, Acute 1 Hereditary Sensory and Autonomic Neuropathies 1 Fanconi Anemia, Complementation Group D1 1 Endometrial Neoplasms 1 Central Nervous System Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Breast Adenocarcinoma 1 Advanced Solid Tumor 1 Advanced Ovarian Cancer 1 ATM Gene Mutation 1

Interventions

ulixertinib 1 tislelizumab 1 talazoparib 1 olaparib 1 lenvatinib 1 erdafitinib 1 atezolizumab 1 Ramucirumab 1 PM 01183 1 Injections 1 IFL protocol 1 Gemcitabine 1 Bosentan 1 BID protein, human 1 Appointments and Schedules 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04497116 2025-10-21

TRESR

Repare Therapeutics

Phase 1/2 Completed

276 enrolled 33 charts

Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡